Abstract:e15000 Background: KC1036 is a novel and selective multi-kinase inhibitor that targets cell proliferation, angiogenesis, metastasis and drug resistance by inhibiting receptor tyrosine kinases (AXLs and VEGFRs) involved in the tumor microenvironment. KC1036 has demonstrated anti-tumor activity in preclinical models of solid tumors, including non-small cell lung cancer (NSCLC). Methods: This phase I, first-in-human study of KC1036 (NCT04387916) enrolled adult patients (pts) with advanced or metastatic solid tumors. This study was comprised of dose escalation (Part A: With the accelerated titration of the 10 mg QD, in which only one patient was enrolled, a standard 3+3 design was applied for 20, 40, 60, and 80 mg QD) followed by dose expansion (Part B) and recommended phase II dose (RP2D) expansion (Part C). The primary safety endpoints were to determine dose limiting toxicities (DLTs) and RP2D. Secondary endpoints included pharmacokinetics (PK) and preliminary efficacy evaluated per RECIST v1.1 criterion. Results: As of November 30, 2022, a total of 41 pts had received at least 1 dose of KC1036 orally with 13 pts in Part A (10 mg [n = 1], 20 mg [n = 3], 40 mg [n = 3], 60 mg [n = 4], 80 mg [n = 3]) and 28 pts in Part B (60 mg [n = 21], 80 mg [n = 7]). In Part A, no DLTs were observed, and the maximum tolerated dose (MTD) has not been reached. Consequently, 60 mg and 80 mg were recommended for Part B. Pts most commonly had NSCLC (31.7%, 13/41), esophageal cancer (14.6%, 6/41), colorectal cancer (12.1%, 5/41). All pts were heavily pre-treated with 65% (27/41) receiving three or more lines of therapy, and average targeted tumor size was 58.7 mm with the largest 162 mm. Of the 41 pts, the median duration of KC1036 exposure was 105.0 days (range, 51.0-168.0). Any-grade TRAEs occurred in 39 pts (95.1%), with 16 pts (39.0%) reported with ≥ Grade 3. The most commonly reported ≥ Grade 3 TRAEs at 60 mg was hypertension (16.7%, 4/24), and that at 80 mg was diarrhea (30.0%, 3/10). PK analysis showed that KC1036 exhibited with dose-proportional increases in exposure over the range of 10 to 40 mg, but increased less proportionally within the range of 40-80 mg. Of 36 pts who had at least one efficacy evaluation, 5 (13.9%) had a best response of partial response (PR) and 24 (66.7%) had stable disease (SD). Thus, ORR was 13.9% (95% CI: 4.7, 29.5) and DCR was 80.6% (95% CI: 64.0, 91.2). Among the 9 evaluable pts with lung adenocarcinoma (6 on 60 mg and 3 on 80 mg), 2 pts had PR, 5 had SD and 2 had progressive disease (PD) as best response. Sustainable PR for 42 weeks was observed in 1 patient with lung adenocarcinoma on 60 mg. Conclusions: KC1036 demonstrated a manageable safety profile and preliminary antitumor activity in pts with advanced solid tumors. Taking safety, efficacy and clinical PK into consideration, 60 mg QD was recommended as RP2D for Part C, and this part was ongoing. Further studies in pts with lung adenocarcinoma would be considered promising. Clinical trial information: NCT04387916 .

First-in-human Phase 1 Study of SPH4336, a Novel Cyclin-Dependent Kinase 4/6 Inhibitor, in Patients with Advanced Solid Tumors.

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Open-label, Dose-Escalation Phase 1a Study of SPH5030, a Tyrosine Kinase Inhibitor (TKI) Targeting HER2, in Patients with HER2 Positive Advanced Solid Tumors.

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors.

Phase I Clinical Study of FC084CSA, a High Selective AXL Kinase Inhibitor That Ameliorates Tumor Microenvironment and Augments the Effectivity of Immunotherapy.

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.

Phase la study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR+/HER2-advanced breast cancer

Dual CK1/PI3K Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Safety, Pharmacokinetics, and Preliminary Activity of CDK4/6 Inhibitor FCN-437c in Chinese Female Patients with HR+HER2- Advanced Breast Cancer (ABC) From Phase Ia Study

Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer

A Phase Ia/Ib Trial of the Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mab), CS1001, in Patients (pts) with Advanced Solid Tumours or Lymphomas

A Phase I Study of a TGF-β Receptor I Kinase Inhibitor YL-13027 in Patients with Advanced Solid Tumors.

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of PRJ1-3024 in Patients with Advanced Solid Tumors.

A First-in-human Phase I Study of CYH33, a Phosphatidylinositol 3-Kinase (PI3K) Α Selective Inhibitor, in Patients with Advanced Solid Tumors.

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

A First-in-human, Phase I, Dose-Escalation Study to Evaluate Pharmacokinetics, Safety, and Tolerability of KD6001, a Novel Anti-Ctla-4 Monoclonal Antibody (mab) in Patients with Advanced Solid Tumors.

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors

A phase I study to evaluate the safety, tolerability, and pharmacokinetics of MSB0254 in Chinese patients with solid tumors.

First-in-human Phase I Study of a Selective VEGFR/FGFR Dual Inhibitor Sulfatinib in Patients with Advanced Solid Tumors.

First-in-human Study of HMPL-295, an ERK1/2 Inhibitor, in Patients with Advanced Solid Tumors: Dose-escalation Results of Monotherapy.